New Recombinant Activated Protein C

Brief Description

Brief Description:

This invention offers a new method to prevent and treat sepsis.

 

Applications:

Sepsis, also known as systemic inflammatory response syndrome (SIRS), is a serious medical condition. It is caused by sustained or dysregulated integrin activation, which result in abnormal neutrophil trafficking, and subsequently, widespread inflammation, blood clotting, organ failure and tissue damage. It occurs in 1 - 2% of all hospitalizations and accounts for as much as 25% of intensive-care unit (ICU) bed utilization. It is a major cause of death in intensive-care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to >60% for septic shock. Current treatment for severe sepsis solely depends on the recombinant human activated protein C (rhAPC). However, the mechanism of its function remains debatable. It also has severe adverse effect, such as bleeding. This new protein is a proprietary recombinant human activated protein for a more potent and better-targeted anti-sepsis therapy, developed by Dr. Minsoo Kim at University of Rochester. The protein binds to neutrophil integrins at high affinity at sites of infection and thereby reduces the neutrophil migration during sepsis that is responsible for the organ malfunction usually responsible for the mortality associated with sepsis.

 

Advantages:

Currently, rhAPC is the only FDA-approved drug to treat severe sepsis. However, the mechanism of its function remains controversial. The severe adverse effect, bleeding, linked to it anticoagulant functions, has limited its use in many needed patients. Unlike rhAPC, the proprietary rhAPC covered here has higher affinities for neutrophil integrins and thus better confine the neutrophils to the site of infection to prevent and/or treat sepsis.

Patent Information:
Title Country Patent No. Issued Date
Preventing and Treating Sepsis United States 8,916,149 12/23/2014
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Minsoo Kim
Keywords: